ارزیابی ایمنی‌زایی واریته تخفیف حدت‌یافته رازی از توکسوپلاسما گوندی در موش Balb/c

نوع مقاله: مقاله کامل

نویسندگان

1 گروه میکروبیولوژی دانشگاه آزاد اسلامی واحد جهرم

2 موسسه تحقیقات واکسن و سرم‌سازی رازی، سازمان تحقیقات، آموزش و ترویج کشاورزی، شیراز، ایران.

3 مربی، گروه میکروبیولوژی ، واحد جهرم ، دانشگاه آزاد اسلامی ، جهرم ، ایران

چکیده

در حال حاضر واکسن زنده توکسوواکس از واریته تخفیف حدت‌یافته‌ی توکسوپلاسما تولید می‌شود. هدف از این پژوهش ارزیابی ایمنی‌زایی واریته‌ی رازی از توکسوپلاسما است که در موسسه رازی شیراز از طریق پاساژهای متوالی و طولانی مدت تولید شده است. بیست و چهار سر موش Balb/c در سه گروه تقسیم شدند. گروه اول کنترل منفی محیط کشت، گروه دوم کنترل مثبت سوش زنده و گروه سوم واریته زنده توکسوپلاسما رازی را دریافت کردند. تمامی موش‌ها به صورت روزانه بررسی و تلفات احتمالی ثبت شد . بیست و هشت روز بعد از تزریق، از تمامی گروه‌های باقی مانده خون‌گیری جهت تست الایزا انجام گرفت و سپس همه گروه‌ها با تزریق سوش حاد چالش شدند. نتایج نشان داد که در گروه کنترل منفی هشت روز پس از چالش تلفات شروع شد و تا روز 14 تمامی موش‌ها در این گروه تلف شدند. در گروه کنترل مثبت مانند گروه اول هشت روز پس از چالش تلفات شروع شد و تا روز 18 تمامی موش‏های این گروه نیز تلف شدند. نتیجه بسیار جالب اینکه در گروه سوم 14 روز پس از چالش تلفات شروع شد و تا یک ماه پس از چالش تنها 50 درصد این گروه تلف شدند. این نتایج نشان داد که واریته توکسوپلاسما رازی منجر به ایجاد ایمنی نسبی در موش گردیده و باعث ایجاد تلفات و بروز بیماری نشد.

کلیدواژه‌ها


عنوان مقاله [English]

Evaluation of Razi attenuated variety of Toxoplasma gondii in Balb/c mice

نویسندگان [English]

  • Arezu Abbasifar 1
  • Mehdi Namavari 2
  • Abbasali Rezayian 3
1 Department of Microbiology, Jahrom Branch, Islamic Azad University, Jahrom, Iran.
2 Razi Vaccine and Serum Research Institute, Agricultural Research, Education and Extension Organization (AREEO), Shiraz, Iran.
3 Department of Microbiology, Jahrom Branch, Islamic Azad University, Jahrom, Iran.
چکیده [English]

Currently, the live vaccine Toxovax is produced from the attenuated variety of Toxoplasma (T.) gondii. The aim of this study was to evaluate the immunogenicity of live variety of T. gondii which was produced through serial passages in cell culture in Shiraz, Razi Institute. Twenty-four Balb/C mice were randomly divided into three groups. Group I was the negative control and received cell culture media. Group II as positive control and group III were inoculated with acute and Razi strains of T. gondii, respectively. All mice were assessed daily and potential mortality was recorded. Twenty-eight days later blood sample were collected from all groups for ELISA and then all mice were challenged with injections of acute strain of T. gondii. The results showed that in the control group, mortality started from day 8 and up to14 days after challenge, all mice of this group died. Similar to the first group, mortality was started in the positive control group 8 days after challenge and all mice died until the day 18. The interesting finding was that the mortality rate was 50% in the third group. These results suggest that the Razi variety of T. gondii caused partial immunity in mice and this variety doesn’t cause disease and mortality in mice.

کلیدواژه‌ها [English]

  • Toxoplasma gondii
  • BALB/c
  • Mice
1. Bartley, P.M., Wright, S., Sales, J., Chianini, F., Buxton , D., and Innes, E.A. 2006. Long-term passage of tachyzoites in tissue culture can attenuate virulence of Neospora caninum in vivo. Parasitology. 133:421-432.
2. Buxton, D. 1993. Toxoplasmosis: the first commercial vaccine. Parasitology Today.9: 335–337.
3. Daneshvar, H., Coombs, G.H., Hagen, P., Philips, S. 2003. Leishmania mexicana and Leishmania major attenuation of wild type parasites and vaccination with the attenuated lines. Journal of Infectious Diseases. 187: 1662–1668.
4. Davison, H.C., Guy,F., Trees, A.J. 1999. In vitro isolation of Neospora caninum from a stillborn calf in the UK. Research in Veterinary Science. 67: 103-105.
5. Değirmenci A1, Döşkaya M, Caner A, Ciçek C, Korkmaz M, Gürüz Y, Uner A. 2011. Toxoplasma gondii RH Ankara: production of evolving tachyzoites using a novel cell culture method. Experimental Parasitology.128:1-8.
6. Dubey, J.P. 2010 Toxoplasma gondii Infections in Chickens (Gallus domesticus): Prevalence, Clinical Disease, Diagnosis and Public Health Significance. Zoonoses and Public Health. 57: 60-73.
7. Dubey JP, Tiao N, Gebreyes WA, Jones JL. 2012. A review of toxoplasmosis in humans and animals in Ethiopia. Epidemiology and Infection. Nov;140:1935-1938.
8. Evans, R., Chatterton, J.M.W., Ashburn, D., Joss, A.W.L., Ho-Yen, D.O.1999. Cell culture system for continuous production of Toxoplasma gondii tachyzoites. European Journal of Clinical Microbiology and Infectious Diseases. 18: 879–884.
9. Hall, R., Ilhan, T., Kivar, E., Wilkie, G., Preston, P.M., Darghouth, M., Somerville, R. and Adamson, R. 1999. Mechanism(s) of attenuation of Theileria annulata vaccine cell lines. Tropical Medicine & International Health. 4: 78–84.
10. Innes, E.A., Lunden, A., Esteban, J., Marks, S., Maley, S., Wrigth, A., Rae, D., Harkins, A., Vermeculen, I., McKendrick, J., Buxton, D. 2001. A previous infection with Toxoplasma gondii does not protect against a challenge with Neospora caninum in pregnant sheep. Parasite Immunology. 23: 121-32.
11. Levin,N.D.and Nye,R.R. 1976.Toxoplasma ranae sp. n. from the leopard frog Rana pipiens Linnaeus, Journal of Protozoology. 23:488-490.
12. Levine, N.D. 1988a. Progress in Taxonomy of the Apicomplexan Protozoa. Journal of Eukaryotic Microbiology. 35:518–520
13. Li J, Han Q,Gong P, Yang T, Ren B, Li S, Zhang X. 2012. Toxoplasma gondii rhomboid protein 1 (TgROM1) is a potential vaccine candidate against toxoplasmosis. Veterinary Parasitology. 184:154–160
14. Lundén A1, Parmley SF, Bengtsson KL, Araujo FG. 1997.Use of a recombinant antigen, SAG2, expressed as a glutathione-S-transferase fusion protein to immunize mice against Toxoplasma gondii. Parasitology Research. 83:6-9.
15. Monney, T., Hemphill,A. 2014.Vaccines against neosporosis: What can we learn from the past studies? Experimental Parasitology,140:52-70.
16. Montoya, J.G., Liesenfeld, O. 2004. Toxoplasmosis. Lancet 363, 1965–1976
17. Namavari, M., Mansourian, M., Khodakaram-Tafti, A., Hosseini, M.H., Rahimiyan, A., Khordadmehr, M., and Lotfi, M. 2012 Application of chicken embryonated eggs as a new model for evaluating the virulence of Neospora caninum tachyzoites. Comparative Clinical Pathology 21:1665-68.
18. Pipano, E., Shkap, V., Kreigel, Y., Leibovitz, B., Savitsky, I., Fish, I. 2002. Babesia bovis and Babesia bigemina persistence of infection in Friesian cows following vaccination with live antibabesial vaccines. Veterinary Journal, 164: 64–68.
19. Ramamoorthy, S., Duncan, R., Lindsay, D.S. and Sriranganathan, N. 2007.Optimization of the use of C57BL/6 mice as a laboratory animal model for Neospora caninum vaccine studies. Veterinary Parasitology. 145: 253-259.
20. Rojo-Montejo,S., Collantes-Fernandez,E., Regidor-Cerrillo,J., Alvarez-Garcia,G., Marugan- Hernandez,V., Pedraza-Diaz,S., Blanco-Muria,J., Prenafeta, A., and Ortega-Mora,L. 2011. Isolation and characterization of a bovine isolate of Neospora caninum with low virulence. Veterinary Parasitology, 159:7-16 .
21. Setasimy, A. & Namavari, M. 2016. Use of chicken embryonated eggs for evaluating the virulence of Toxoplasma gondii. Journal of Parasitic Diseases. 40: 1223–1225
22. Snow, R.W., Guerra, C.A., Noor, A.M., Myint, H.Y., Hay, S.I. 2005. The global distribution of clinical episodes of Plasmodium falciparum malaria. Nature. 434:214–217.
23. Wallance,G.D.1973.The role of the cat in the natural history of Toxoplasma gondii, The American Journal of Tropical Medicine and Hygiene. 22:313-322
24. Wang, HL, Wang, YJ., Pei,YJ, Bai, JZ., Yin, LT., Guo, R., Yin, GR. 2016. DNA vaccination with a gene encoding Toxoplasma gondii Rhoptry Protein 17 induces partial protective immunity against lethal challenge in mice. Parasite. 23:4.
25. Wilkins, M.F.,O Connel, E., Te Punga, W.A. 1988. Toxoplasmosis in sheep III. Further evaluation of the ability of a live Toxoplasma gondii vaccine to prevent lamb losses and reduce congenital infection following an experimental oral challenge. New Zealand Veterinary Journal. 36:86-89.